{"filing":{"accession_number":"0001193125-26-347984","cik":"0001434316","ticker":"FATE","company_name":"FATE THERAPEUTICS INC","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"fate-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1434316/000119312526347984/fate-20260813.htm"},"events":[{"id":27559,"run_id":25127,"accession_number":"0001193125-26-347984","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses financial results including cash position ($153.8M), revenue ($2.1M), operating expenses ($33.2M), and net loss ($30.2M per share), along with business updates on clinical programs (RECLAIM-LN, FT839, FT836) and corporate developments (Laura Hamill board appointment). The press release is attached as Exhibit 99.1 and covers both financial results and material operational milestones.","company_name":"FATE THERAPEUTICS INC","ticker":"FATE","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29142,"accession_number":"0001193125-26-347984","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses financial results including cash position ($153.8M), revenue ($2.1M), operating expenses ($33.2M), and net loss ($30.2M per share), along with business updates on clinical programs (RECLAIM-LN, FT839, FT836) and corporate developments (Laura Hamill board appointment). The press release is attached as Exhibit 99.1 and covers both financial results and material operational milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:33:37.677995+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29142,"accession_number":"0001193125-26-347984","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 ended June 30, 2026. The filing discloses financial results including cash position ($153.8M), revenue ($2.1M), operating expenses ($33.2M), and net loss ($30.2M per share), along with business updates on clinical programs (RECLAIM-LN, FT839, FT836) and corporate developments (Laura Hamill board appointment). The press release is attached as Exhibit 99.1 and covers both financial results and material operational milestones.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T12:33:37.677995+00:00","company_name":"FATE THERAPEUTICS INC","ticker":"FATE","filing_date":"2026-08-13"}]}